Opening a new era | Professor Wang Yan's team from Xiamen Cardiovascular Hospital has successfully completed the first enrollment of Shanghai Surgipulse Robotics Robot Assistance System

The TAVR²S conference witnessed a milestone achievement. Professor Wang Yan's team from Xiamen Cardiovascular Hospital Xiamen University (referred to as "XMCH"), collaborated with Professor Luigi Pirelli from NewYork-Presbyterian/Columbia University Medical Center. Together, they successfully performed intervention procedure using the structural heart robotic-assisted system developed by Shanghai Surgipulse Robotics on a patient with severe degenerative mitral regurgitation (DMR). The patient recovered well after the procedure.

This procedure marked the first case enrolled in the national multicenter registration clinical trial for the Shanghai Surgipulse Robotics structural heart robotic-assisted system. During the operation, Professor Wang Yan's team, with their exceptional skills, worked in close multidisciplinary collaboration with the anesthesia department, echocardiography team, cardiac intensive care unit, and interventional nursing team. They precisely operated the robotic-assisted platform to successfully complete the mitral regurgitation intervention, effectively verifying the system's safety and efficacy in clinical applications.

In December 2023, Professor Wang Yan's team successfully completed the world's first robotic-assisted transcatheter edge-to-edge mitral valve repair using this system, having previously conducted six exploratory clinical trials. During the 2024 TCT conference in the United States, Professor Wang Yan presented the clinical data of the robotic-assisted system for the first time, attracting widespread international attention. At the TAVR²S conference, Professor Luigi Pirelli personally attended to observe and participate in the clinical trial intervention, with plans to introduce the system to the United States for further clinical trials.

The success of this first enrolled case not only brings new treatment hope to patients with mitral regurgitation but also lays a solid foundation for the multicenter registration clinical study led by XMCH. Following the completion of the first enrolled case, the research team swiftly proceeded with the official registration clinical trial. Through the joint efforts of the multidisciplinary team, the study's first officially registered patient was successfully enrolled. The enrollment of these two patients marks the official launch of the multicenter registration clinical study for the structural heart robotic-assisted system, led by President Wang Yan of XMCH.